×

Biotech and Pharmaceuticals Pharmaceuticals

  • Bugs Bunny

    Could a carrot-chomping Bugs Bunny become a drug pitchman? Well, maybe, if the small Israeli company Protalix BioTherapeutics could pay Warner Brothers enough money for Bugs' services.

  • Zyban Prescribing Information

    Today the Food and Drug Administration announced that Pfizer's Chantix and GlaxoSmithKline's Zyban will carry new warnings about mental side effects. Not just any old warnings, but so-called "Black Box" warnings. Or, at least, that's what we in the news media used to call them. Until the FDA called us out today.

  • Sanofi Aventis

    Shares of Sanofi-Aventis are getting a little investor injection on the back of the emergency release of the Lantus diabetic insulin studies late last Friday.

  • Sanofi Aventis

    Shares of the French drugmaker are getting pummeled over at least three analyst reports identifying a leak about a study or studies that could go public soon. Their research suggests the data is related to a suspected or "theoretical" higher cancer risk associated with SNY's Lantus.

  • boston_scientific.jpg

    Man, it's gotta hurt when the publicly-traded company you've been leading for years announces you're stepping down and investors pop the champagne corks.

  • Rabies in the Americas 2009

    ACC, ADA, AHA, ASCO, ICAD, TCT. That's just a handful of the acronyms and abbreviations for scientific and medical conferences that I've attended over the years. But this year I might be able to add RITA to my dance card. I'd never heard of her (it) before this morning when I got this press release from Crucell, which owns technology for faster, better, cheaper vaccine manufacturing.

  • Apple CEO Steve Jobs introduces the new iPod Nano in San Francisco, Tuesday, Sept. 9, 2008.

    The growing, influential role of Twitter has never been more evident than during the recent Iranian uprising. But did the story that "The Wall Street Journal" broke last Friday night about Apple's Steve Jobs getting a liver transplant actually appear on Twitter first?

  • Cramer works the crowd during his "Mad Money: It's a Family Affair" special.

    Cramer, ever the contrarian, disagrees with that sentiment. He prefers his stocks at a different temperature.

  • Healthcare stocks rebound, so is significant reform dead? Healthcare stocks have been moving off their lows since Tuesday and are up significantly today after moving almost straight down in June.

  • Two days after the FDA ordered Matrixx Initiatives' Zicam off the market the story remains one of the most emailed articles on "The New York Times" website. And the company seems to still be trying to find its corporate crisis footing.

  • Wondering what happened to the rally? Cramer puts stocks’ sudden declines into perspective.

  • Zicam

    I was an early adopter of Zicam when it came on the market 10 years ago. Whenever I felt a cold coming on, I'd load up on the stuff along with Vitamin C and zinc lozenges. So, last night I went searching through the bathroom cabinets to find my Zicam stash to toss it in the trash per the FDA's advisory.

  • While the charts say one thing, Cramer thinks something entirely different.

  • Doctor examines a man at a public health center set up to check for swine flu symptoms

    Concerned over the surge of phony swine flu treatments hawked on the Internet, the Food and Drug Administration has ordered dozens of Web site operators to stop making fraudulent claims, leading to a drop in the number of scams.

  • Lipitor

    I have a confession to make. I try to be as transparent as possible, to share as much information as I can about how the sausage is made. To that end, on at least a few occasions I’ve mentioned on this blog and on CNBC, that I’ve been on 10 milligrams of Lipitor.

  • The Dow eked out a gain Friday, bumping it into positive territory for the year, as Bank of America shares  rallied. But techs, energy and commodities retreated as crude oil dropped to around $72 a barrel.

  • Stocks opened lower Friday as crude oil dropped below $71 a barrel and banks dragged after Bank of America lowered its outlook for the sector.

  • genentech_slide34.jpg

    This morning the apparently Red Bull-fueled (or maybe he's a Starbucks triple-shot guy) biotech analyst at Deutsche Bank, Dr. Mark Schoenebaum, did a deep dive for clients in a presentation he called, "Getting ready for summer!"

  • Stocks opened lower Friday as crude oil dropped below $71 a barrel and banks dragged after Bank of America lowered its outlook for the sector.

  • Futures pointed to a negative open for Wall Street Friday as crude oil dropped below $71 a barrel and banks dragged after Bank of America lowered its outlook for the sector.